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Objective: Demonstrate that successful soft contact lens wearers using competitive multipurpose 
solutions report improvement in comfort with OPTI-FREE® RepleniSH® Multi-Purpose Dis-
infecting Solution (MPDS).
Methods: This 30-day, multicentered, open-label study enrolled 109 eligible soft contact lens 
wearers using COMPLETE® Multi-Purpose Solution (MPS) Easy Rub® or ReNu MultiPlus® 
MPS. The test solution (OPTI-FREE® RepleniSH® MPDS) was dispensed for use in place of 
habitual care solutions. Subjects assessed their experience with their habitual solution (baseline) 
and the test solution (Day 30) using Likert-style questions. Contact lens acuity and biomicroscopy 
findings were recorded at each visit.
Results: The test solution was associated with a statistically significant improvement in 
instillation comfort (P = 0.02), end of day comfort (P  0.0001), clear vision (P  0.0001) 
and overall satisfaction (P  0.001). Subjects reported the test solution enhanced their overall 
lens-wearing experience more effectively than their previous solution (P  0.0001) and that 
they would continue test solution use after the study (P  0.0001).
Conclusions: The test solution was effective at improving comfort and overall contact lens 
experience compared to COMPLETE® MPS Easy Rub® or ReNu MultiPlus® MPS in successful 
contact lens wearers. These results indicate that changing contact lens care solutions, even in 
successful lens wearers, may improve comfort and overall lens-wearing experience.
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Contact lens comfort has been the focus of many clinical studies and review articles.1–6 
This is not surprising as it is estimated that, while there are 3.5 million new contact lens 
wearers each year, approximately two to three million established lens wearers drop 
out of contact lens wear. Dryness and discomfort are cited as key reasons.7,8 For those 
who remain in contact lenses, ocular dryness continues to be a significant complaint, 
with up to four out of five lens wearers affected,3 and one in four contact lens wearers 
finding that it adversely affects their wearing time.9
Comfort in successful contact lens wearers should not be taken for granted.9 
A patient who wears their lenses on a full-time basis over a certain wearing period is 
commonly considered to be a successful lens wearer. Comfort is a dependent variable 
and therefore subject to fluctuations during contact lens wear. Patient-specific factors 
as well as external factors can influence subjective comfort to varying degrees, even 
in successful full-time contact lens wearers.9 Most commonly, successful contact lens 
wearers experience a decrease in comfort towards the end of the day.2,10 While it may Clinical Ophthalmology 2010:4 48
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or may not be enough to reduce wearing time, this decrease 
in comfort is undesirable nonetheless. Maintaining and 
optimizing lens-wearing comfort for successful contact lens 
wearers is crucial to minimize contact lens dropout, and is 
the focus of the current study.5
Contact lens practitioners have an important role in sup-
porting and maintaining the success of their contact lens 
wearers. This can be particularly difficult when patients do 
not voice complaints during their annual exams. Effective 
questioning at contact lens visits can elucidate otherwise 
unrecognized issues and generate possible opportunities for 
improvement in patient comfort. Similarly, a solid under-
standing of a patient’s medical history, environment and 
lifestyle are valuable tools for predicting and managing a 
patient’s ongoing success. In addition, thoughtful choice of 
a contact lens and its partner solution contribute to contact 
lens-wearing success.
Advances in contact lens material technology, providing 
greater flexibility in lens wear schedules and improved health 
benefits, allow practitioners to choose lenses ideally suited 
to a patient’s individual requirements. These new materials 
have demonstrated tangible improvements in patient com-
fort, as well as in a patient’s overall satisfaction.11–16 While 
the optimal choice of contact lens is directly related to a 
patient’s satisfaction, it is very important to consider the 
synergistic relationship between contact lens and lens care 
solution. Multipurpose solutions comprise different formula-
tions that may provide additional benefits, extending contact 
lens-wearing success.17
In this investigation into lens-wearing comfort, two 
polyhexamethylene biguanide (PHMB) (0.0001%)-preserved 
lens care solutions, COMPLETE® Multi-Purpose Solution 
(MPS) Easy Rub® (AMO, Santa Ana, CA, USA) and 
ReNu MultiPlus® MPS (Bausch & Lomb, Rochester, NY, 
USA), were compared with a third solution, OPTI-FREE® 
RepleniSH® Multi-Purpose Disinfecting Solution (MPDS; 
Alcon Laboratories Inc, Fort Worth, TX, USA), preserved 
with Polyquaternium-1 (POLYQUAD®) and myristamidopro-
pyl dimethylamine (ALDOX®) 0.0005%. PHMB is a broad-
spectrum cationic antimicrobial agent. It electrostatically 
binds to (and in turn destroys) the cytoplasmic membranes 
of microbes, disrupting metabolic activity and resulting in 
irreversible loss of intracellular components.18 POLYQUAD® 
is a quaternary ammonium compound. An antimicrobial 
agent with attenuated toxicity, it reduces the surface tension 
at interfaces and denatures microbial cell wall proteins, 
causing microbial cell death.18 ALDOX®, a cationic amido-
amine, is an antifungal/anti-amoebic that works in synergy 
with POLYQUAD® in OPTI-FREE® RepleniSH® MPDS to 
meet the highest standard of ISO and FDA criteria for the 
disinfection of bacteria and fungi.19
Additionally, OPTI-FREE® RepleniSH® MPDS contains 
a TearGlyde® reconditioning system, incorporating Tetronic 
1304 and C9-ED3A (nonanoyl ethylenediaminetriacetic 
acid). The components are attracted to the surface and matrix 
of silicone hydrogel and traditional hydrogel lenses and form 
a network to maintain a thin layer of moisture on the lens 
surface throughout the day. OPTI-FREE® RepleniSH® MPDS 
has been shown to increase contact lens comfort in the most 
common hydrogel material among those who experience 
discomfort20 and maintain a low wetting angle after 14 hours 
of lens wear as demonstrated in ex vivo clinical studies.21
OPTI-FREE® RepleniSH® MPDS is a new generation 
contact lens solution formulated to provide benefits in the key 
areas of lens wettability,22–25 lens cleaning,19,26 and biocompat-
ible disinfection.27 In addition, it has demonstrated clinical 
biocompatibility with both traditional hydrogel and silicone 
hydrogel lens materials.25,26 The current study investigates 
the patient benefit of transitioning successful full-time, daily 
wear, soft contact lens wearers currently using competitive 
older-generation multipurpose solutions to OPTI-FREE® 
RepleniSH® MPDS.
Methods
Materials
The test solution was OPTI-FREE® RepleniSH® MPDS. 
ReNu MultiPlus® MPS and COMPLETE® MPS Easy Rub® 
were the comparative solutions. Subjects wore their habitual 
soft contact lenses throughout the study.
study population
This 30 day, open label study involving six optometric prac-
tices enrolled a total of 114 successful contact lens wearers. 
Patients able to wear their lenses on a full time basis (eight 
hours per day and seven days per week) were considered 
to be successful. There were 109 evaluable subjects in the 
study. One hundred eight (108) of these completed the 
questionnaire. Eligible subjects were aged between 18 and 
65 years and were successful soft contact lens wearers using 
either ReNu MultiPlus® MPS or COMPLETE® MPS Easy 
Rub® as their usual care solution, and free of any contact 
lens-related symptoms with regard to comfort and vision. 
Subjects were required to wear soft lenses on a daily wear 
basis, with a two-weekly or monthly replacement schedule 
and wore their habitual soft lenses for at least one month 
prior to study enrollment. They were required to wear their Clinical Ophthalmology 2010:4 49
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lenses for at least eight hours per day, seven days per week. 
Subjects using ReNu MultiPlus® MPS or COMPLETE® 
MPS Easy Rub® for at least 30 days prior to enrollment were 
eligible. Patient distribution at each site is summarized in 
Table 1. The mean age of subjects was 36 years and 71% of 
the subjects were female.
As a prerequisite for enrollment, subjects were required 
to have best corrected Snellen visual acuity of 20/30 or better 
in each eye; to be in good health; and to continue any pre-
enrollment systemic medication regimens during the study. 
Attendance at both study visits and the completion of study 
questionnaires was also required. Subjects maintained during 
the study any regimen of rewetting drops and/or topical allergy 
drops that had been instilled during the 30 days prior to the 
study. No topical ocular drops, other than rewetting drops 
and/or topical allergy drops, were allowed during the study.
Patients wearing contact lenses on an extended wear 
(overnight) basis and those wearing monovision were excluded, 
as were those patients who had participated in another clinical 
trial within the 30 days prior to enrollment. Further exclusion 
criteria included a history of allergy or sensitivity to any test 
solution ingredient and, with the exception of allergy and/or 
rewetting drops, use of any topical ocular medications in the 
seven days prior to enrollment. Subjects who had changed 
brands of cosmetics or those who had modified their systemic 
medications within 30 days prior to enrollment were excluded, 
as were subjects with significant active corneal, eyelid or 
anterior segment infection or inflammation.
Safety was established by assessment of visual acuity, 
biomicroscopy and adverse events. The study was performed 
in compliance with the ethical principles of the Declaration 
of Helsinki and was approved by the Southwest Independent 
Institution Review Board. Informed consent was obtained 
from all patients prior to enrollment.
Procedures
At the baseline visit (Visit 1–Day 0), a subject’s preliminary 
eligibility was established and demographic information 
recorded. Baseline measurements including distance visual 
acuity with contact lenses and biomicroscopy findings (lids, 
cornea and bulbar conjunctiva) were recorded. Eligible sub-
jects completed study questionnaire A (Table 2a) to deter-
mine their baseline subjective experience with their habitual 
contact lenses and care regimen.
Subsequently, patients were dispensed a 30-day supply 
of their habitual contact lenses, a new lens case, 20 oz of test 
solution to use in place of their habitual lens-care solution, 
and were instructed (both orally and in writing) on the use 
of the test solution and on appropriate lens care.
The evaluation visit (Visit 2–Day 30) was conducted 
30 ± 3 days after the baseline visit. Results for distance 
visual acuity with contact lenses as well as for biomicroscopy 
assessment of the lids, cornea and bulbar conjunctiva were 
recorded and any adverse events assessed. Subjects completed 
study questionnaire B (Table 2b), assessing their contact lens-
wearing experience during the study period and comparing 
that experience with their previous solution experience.
Questionnaires
Subjects completed a questionnaire at the baseline (study 
questionnaire A) and evaluation visits (study questionnaire B) 
to determine patient benefit (Table 2b). Study questionnaire 
A included four Likert-style questions assessing comfort, 
vision, and overall lens-wearing experience. These questions 
have been used previously to subjectively assess lens wear.26,27 
The evaluation visit questionnaire, study questionnaire B, 
included the baseline questions and two preference questions 
(Table 2b). Questionnaires were completed by the subject 
before any ocular assessments were made at each visit.
Distance visual acuity
Contact lens visual acuity was measured for distance. Acuities 
were measured using a Snellen letter chart (calibrated) for 
each eye individually under photopic lighting conditions.
Biomicroscopy
Subjects were evaluated to rule out any active ocular pathol-
ogy that would interfere with successful contact lens wear. 
This involved a systematic examination of the eyelids, bulbar 
and palpebral conjunctiva and cornea. Findings were recorded 
as either ‘normal’ or ‘abnormal’. Subjects with abnormal 
findings were excluded from the study.
Adverse events
Adverse events were considered to be any unfavorable or 
unexpected medical occurrence during the test solution 
Table 1 enrollment
Site Number of patients
1 25
2 20
3 16
4 12
5 30
6 11
Total 114Clinical Ophthalmology 2010:4 50
Corbin et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
period of use. For enrolled subjects, any change from baseline 
in the clinical findings deemed unfavorable was considered 
an adverse event and recorded.
statistical methods
A two-sided Wilcoxon rank sum test was used for compari-
sons between baseline and Day 30 assessments from patient 
questionnaires. A chi-squared test was used for test of equal 
proportions for the two comparison questions assessed only 
at Day 30. A paired t-test was used for within-patient changes 
in visual acuity. All tests were two-sided with a confidence 
level set to 95%. A P-value of 0.05 was taken as statistically 
significant. Statistical analysis was performed by an inde-
pendent biostatistician using SAS software (SAS Institute, 
Cary, NC, USA).
Results
A total of 114 patients were enrolled at six study sites. Five 
subjects were excluded from the analysis (Table 3). Habitual 
lenses worn by the patients are shown in Table 4. There were 
five reported adverse events, all nonserious (Table 5). For the 
remaining 109 subjects, 108 completed study questionnaire 
A and 109 completed study questionnaire B.
At the Day 30 visit, there was no significant decrease 
in visual acuity (OD, P = 0.20; OS, P = 0.52). Most sub-
jects achieved 20/20 both at baseline and at Day 30 (range 
20/15–20/30). With the exception of the ocular adverse events 
Table 2a study questionnaire A
Strongly agree Agree Neutral Disagree Strongly disagree
1.    My lenses are comfortable upon instillation 1 2 3 4 5
2.    My lenses feel comfortable at the end of the lens-wearing day 1 2 3 4 5
3.    My vision is clear at the end of the lens-wearing day 1 2 3 4 5
4.    I am satisfied with my overall lens-wearing experience 1 2 3 4 5
Table 2b study questionnaire B
Strongly agree Agree Neutral Disagree Strongly disagree
1.    My lenses are comfortable upon instillation 1 2 3 4 5
2.    My lenses feel comfortable at the end of the lens-wearing day 1 2 3 4 5
3.    My vision is clear at the end of the lens-wearing day 1 2 3 4 5
4.    I am satisfied with my overall lens-wearing experience 1 2 3 4 5
5.      The study product enhances my overall lens-wearing  
experience more effectively than my previous solution
1 2 3 4 5
6.    i will continue to use the test solution after this study 1 2 3 4 5
Table 3 subject accountability
Reasons for study exclusion  Number  
of patients
Discontinued contact lens wearing during study 1
Received treatment during study that might interfere 
with study outcome
1
Withdrawn 3
Table 4 habitual lenses
Brand # of Patients
Silicone hydrogel lenses
Acuvue Advance  5
Acuvue Oasys 31
O2 Optix 3
Air Optix 2
night & Day 3
PureVision 6
Traditional hydrogel lenses
Acuvue 2  20
Frequency 55 5
Soflens (66, 38, MF) 22
Precision UV 2
Biomedics (55, XC) 2
Proclear  6
Freshlook  1
Definition AC 1Clinical Ophthalmology 2010:4 51
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reported, there were no significant changes in biomicroscopy 
ratings during the study.
Responses to study questionnaire A (Day 0) were 
compared with those from study questionnaire B (Day 30). 
Subjects rated the test solution significantly better for all four 
subjective statements, including lens instillation comfort 
(P = 0.02, Figure 1); end of day comfort (P  0.0001, 
Figure 2); clear vision at the end of the lens-wearing day 
(P  0.0001, Figure 3) and overall satisfaction (P  0.001, 
Figure 4) compared to their previous solution.
For the two direct comparison questions asked only at 
Day 30, 71% of the patients agreed that the test solution 
enhanced the overall lens-wearing experience more effectively 
than the previous solution (P  0.0001, Figure 5); and 81% 
of the patients reported that they will continue to use the test 
solution after the study (P  0.0001, Figure 6).
Ninety-three patients agreed that their lenses with 
the previous solution were comfortable upon instillation. 
Of those, 68% reported that the test solution was more effec-
tive in enhancing their lens-wearing experience and 78% 
said that they would continue to use the test solution. It was 
87% and 93%, respectively, of 15 patients who were neutral 
or did not find that their lenses with their previous solution 
were comfortable upon instillation.
Sixty-four patients agreed that their lenses felt com-
fortable at the end of the lens-wearing day when using 
Table 5 List of reported adverse events
Patient ID Event Severity Relation to study drug
116 Bilateral viral conjunctivitis Moderate not related
211 Left eye seemed blurred and lens felt dirty Mild not related
306 stinging upon instillation of OU Mild Related
401 Left eye acute hordeolum in the lower lid Moderate not related
606 Burning sensation when putting on contacts in the morning Mild Related
Abbreviation: OU, bilateral.
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Figure 1 insertion comfort. “My lenses are comfortable upon insertion.”
Note: P-value = 0.024.Clinical Ophthalmology 2010:4 52
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Figure 2 end of day comfort. “My lenses feel comfortable at the end of the lens-wearing day.”
Note: P-value  0.0001.
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Figure 3 end of day vision. “My vision is clear at the end of the lens-wearing day.”
Note: P-value  0.0001.Clinical Ophthalmology 2010:4 53
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the previous solution. Of those, 63% reported that the test 
solution was more effective in enhancing their lens-wearing 
experience; and 77% agreed that they would continue to use 
the test solution. It was 82% and 86%, respectively, of 44 
patients who were neutral or did not agree that their lenses 
felt comfortable at the end of the lens-wearing day when 
using their previous solution.
Seventy-two patients agreed that their vision was clear at 
the end of lens-wearing day when using their previous solu-
tion. Of those, 64% reported that the test solution was more 
effective in enhancing their lens-wearing experience; and 
79% agreed that they would continue to use the test solution. 
It was 83% and 83%, respectively, of 36 patients who were 
neutral or did not agree that their vision was clear at the end 
of the lens-wearing day when using their previous solution.
Eighty-seven patients agreed that they were satisfied 
overall with their previous solution. Of these, 67% rated the 
test solution more effective in enhancing their lens-wearing 
experience, and 77% agreed that they would continue to 
use the test solution. It was 86% and 95%, respectively, of 
21 patients who were neutral or did not agree that they were 
satisfied overall with their previous solution.
Results of the within-subject, before-after comparisons 
indicated that most subjects responded ‘strongly agree’ or 
‘agree’ to questions concerning the test solution, regardless 
of their rating of the previous solution.
Discussion
Terry and colleagues28 suggest, that when gauging success 
by wearing time alone, many ‘successful’ lens wearers may 
instead be ‘contact lens survivors’, enduring rather than 
enjoying contact lens wear. Even though contact lens wear-
ers may be able to wear their lenses full-time, if they expe-
rience discomfort, they are at risk of dropping out of lens 
wear. Pritchard and colleagues1 found that 12% of contact 
lens patients discontinued lens wear within five years of the 
initial fitting due to dryness and discomfort symptoms. Lens-
wearing comfort appears to be a better predictor of ongoing 
successful wear, demonstrated by Brennan and colleagues,4 
thus highlighting the importance of optimizing comfort in 
contact lens wearers.
One of the key factors that contributes to comfort is the 
health and integrity of the corneal surface.25,29,30 With the 
introduction of new lens materials, the biocompatibility of 
lens materials and lens care solutions has generated con-
siderable clinical interest as it has become apparent that 
certain lens/solution combinations can cause disruption to 
the epithelium.31,32 In 2002, Jones and colleagues31 found 
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Figure 4 Satisfaction. “I am satisfied with my overall lens-wearing experience.”
Note: P-value = 0.0009.Clinical Ophthalmology 2010:4 54
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moderate to severe corneal staining in 37% of subjects 
when a multi-purpose solution with the preservative 
PHMB was used with PureVision® (Bausch & Lomb) 
silicone hydrogel lenses. More recently, a comprehensive 
analysis of FDA-cleared multi-purpose solutions with both 
silicone hydrogel materials and traditional hydrogel lenses 
was undertaken by Andrasko and Ryen,25,33 revealing that 
different lens/solution combinations can cause varying 
degrees of corneal staining.
Despite its high level of antimicrobial efficacy, OPTI-
FREE® RepleniSH® MPDS has demonstrated biocompat-
ibility with the ocular surface and has FDA clearance 
for use with silicone hydrogel and soft lenses. Hall and 
colleagues34 demonstrated that OPTI-FREE® RepleniSH® 
MPDS sustains corneal barrier function by minimizing cor-
neal damage and maintaining normal corneal permeability. 
OPTI-FREE® RepleniSH® MPDS has also been shown to 
exhibit minimal corneal staining with all tested lens/solution 
combinations.32,33
Staining using fluorescein is routinely used to evaluate 
epithelial integrity,34–36 yet the significance of solution-related 
staining has been debated. While staining can be viewed as 
a sign of corneal damage presenting a pathway for possible 
infection, a link between solution-related staining and infec-
tion has not been shown.
Nevertheless, in light of recent research, it is in a practi-
tioner’s best interest to minimize corneal staining in contact 
lens wearers. In 2007, Carnt and colleagues37 showed staining 
was associated with a higher incidence of infiltrative ocular 
events. In addition, Andrasko and Ryen25 found a moderate 
correlation between lens/solution-induced staining and 
reduced comfort. The implication for contact lens wearers is 
that higher levels of staining may increase the risk of infiltra-
tive events and comfort-related problems. Minimizing corneal 
staining through careful consideration of the biocompatibility 
of the lens and lens care solution combination may contribute 
to improved comfort and contact lens-wearing success.
In the current study of 109 successful lens wearers who 
habitually used a competitive multipurpose solution, it is 
noteworthy that upon questioning, several subjects reported 
discomfort and dissatisfaction. In particular, 15 subjects 
were neutral or disagreed that their previous solution was 
comfortable on instillation and 21 were neutral or not 
satisfied with their previous solution. Following the use of 
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Figure 5 Overall experience. “The study product enhances my overall lens-wearing experience more effectively than my previous product.”
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OPTI-FREE® RepleniSH® MPDS during the study period, 
of the 15 aforementioned subjects, 87% (13/15) rated the 
test solution more effective at enhancing their overall 
lens-wearing experience and 93% (14/15) agreed that they 
would continue to use the test solution. Of the 21 subjects 
dissatisfied with their previous product, 86% (18/21) rated 
the test solution more effective in enhancing their overall 
lens-wearing experience and 95% (20/21) agreed that they 
would continue to use the test solution.
These results show the improvement in subjective 
comfort in lens wearers who are neutral or not satisfied with 
their current lens care solution with the use of OPTI-FREE® 
RepleniSH® MPDS. It also highlights the importance of 
effective questioning of successful contact lens wearers to 
elicit and address any comfort-related issues.
Perhaps even more notably however, successful lens 
wearers who did report end of day comfort, clear vision at 
the end of a day’s wear, or who reported satisfaction overall 
with their habitual lens-wearing experience also found a 
significant improvement in their lens-wearing experience 
after 30 days of OPTI-FREE® RepleniSH® MPDS use. 
Of the 93 subjects who agreed that the previous solution was 
comfortable upon instillation, 68% preferred the test solution 
for enhancing their overall lens-wearing experience and 78% 
will continue to use the test solution. Of the 87 patients who 
were satisfied with their previous solution, 67% found the 
test solution enhanced their overall lens-wearing experience 
and 77% will continue to use the test solution.
These results indicate that satisfied contact lens wearers 
are likely to experience even greater satisfaction with lens 
wear when using OPTI-FREE® RepleniSH® MPDS. The 
implication for a contact lens practice is that proactive 
recommendation of OPTI-FREE® RepleniSH® MPDS for 
successful contact lens wearers is likely to further enhance 
comfort and overall contact lens-wearing experience.
These data are consistent with the earlier findings of Kern 
and colleagues38 where patients were asked to switch from 
their habitual solution to OPTI-FREE® RepleniSH® MPDS. 
In a questionnaire given to successful contact lens wearers, 
3,132 patients responded to rate their experience with OPTI-
FREE® RepleniSH® MPDS. Of these respondents, 91% rated 
their lenses as feeling clean, 91% found it to be gentle on 
the eyes, 84% felt their lenses were moist, 83% noted lasting 
comfort and 58% agreed that they could wear their lenses 
longer with OPTI-FREE® RepleniSH® MPDS.
In addition to biocompatibility, lens cleanliness contrib-
utes to comfortable contact lens wear. Excessive deposits can 
degrade lens surface quality and negatively impact comfort. 
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Figure 6 solution preference. “i will continue to use the study solution after this study.”
Note: P-value  0.0001.Clinical Ophthalmology 2010:4 56
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The efficacy of OPTI-FREE® RepleniSH® MPDS in lens 
protein removal has been determined using in vitro lysozyme 
deposition models and ex vivo clinical studies that compared 
OPTI-FREE® RepleniSH® MPDS with other marketed 
multi-purpose solutions. OPTI-FREE® RepleniSH® MPDS 
demonstrated the greatest cleaning efficacy (as defined as 
a percentage of lysozyme removed with cleaning).21 In a 
separate study involving a seven-day regimen of immersion 
in lysozyme solution followed by soaking, OPTI-FREE® 
RepleniSH® MPDS demonstrated greater cleaning efficacy 
than other studied solutions.35 A separate study investigat-
ing lipid removal showed that a POLYQUAD®/ALDOX® 
disinfection system was able to reduce deposition of the 
tear film lipid (cholesterol oleate) from senofilcon A, sili-
cone hydrogel lenses by 36% compared to a peroxide-based 
system, when both were used as a no-rub regimen.39 In a 
clinical evaluation of long-term users of solutions containing 
POLYQUAD® or PHMB, subjects using OPTI-FREE® 
solutions had significantly fewer deposits than those using 
PHMB-based solutions.24 These difference in lens cleaning 
performance between OPTI-FREE® RepleniSH® MPDS and 
other solutions may be a contributing factor in the higher 
comfort ratings for OPTI-FREE® RepleniSH® MPDS in the 
current study.
The primary limitation of this study was its open label 
design. Subjects knew that they were using a new solution 
which could influence the study outcomes. In addition, due to 
the nature of the study design there was not a true control. This 
study did attempt to simulate real world conditions in regard 
to patient lens care regimens. Additional double-masked, 
controlled studies could provide additional insights into the 
effect of a lens care regimen on patient acceptance.
The data from the current study exemplify the benefits 
of OPTI-FREE® RepleniSH® MPDS that can contribute to 
increased comfortable wearing time through biocompatibility,25 
effective cleaning,21,24 and lens wettability in silicone hydrogel 
and hydrogel lens wearers.22,23
Solutions are often overlooked as a means of addressing 
comfort issues in contact lens wearers. Understanding the 
relationship lenses and lens care can have on comfort will 
assist contact lens practitioners in tailoring a lens care plan 
suited to each individual patient. Educating a patient on 
these benefits through effective communication may in turn 
enhance compliance.
The financial benefit of contact lens wearers to a practice 
has been documented. Contact lens patients return greater 
revenue than those who wear spectacles alone. Contact lens 
dropouts erode potential income. Nurturing contact lens 
wearers to get the most out of their contact lens-wearing 
experience is not only professionally rewarding but will 
contribute to practice growth.
Conclusion
Compared to their habitual contact lens solution, success-
ful contact lens wearers increased in comfort and overall 
lens-wearing satisfaction after 30 days of using OPTI-
FREE® RepleniSH® MPDS. This study provides evidence 
that proactive transitioning of patients to OPTI-FREE® 
RepleniSH® MPDS may lead to greater contact lens-wearing 
satisfaction.
OPTI-FREE® RepleniSH® MPDS provides practitioners 
with an opportunity to meet and anticipate patient needs, 
thus reducing the risk of patient dropouts and providing an 
effective means for practitioners to grow and maintain a 
successful contact lens practice.
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